[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Myriad Genetics Inc (MYGN)

Myriad Genetics Inc (MYGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting

SALT LAKE CITY, May 27, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces it will share data demonstrating the...

MYGN : 4.28 (+7.81%)
Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)

SALT LAKE CITY, May 26, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces the launch of the Prolaris + AI Test...

MYGN : 4.28 (+7.81%)
1 Unprofitable Stock to Consider Right Now and 2 We Turn Down

1 Unprofitable Stock to Consider Right Now and 2 We Turn Down

GEVO : 1.8400 (-1.08%)
MYGN : 4.28 (+7.81%)
PI : 142.67 (-5.52%)
Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life

SALT LAKE CITY, May 15, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, joins forces with Nobody Wants This actress...

MYGN : 4.28 (+7.81%)
Myriad Genetics’s Q1 Earnings Call: Our Top 5 Analyst Questions

Myriad Genetics’s Q1 Earnings Call: Our Top 5 Analyst Questions

MYGN : 4.28 (+7.81%)
3 of Wall Street’s Favorite Stocks with Open Questions

3 of Wall Street’s Favorite Stocks with Open Questions

AR : 36.76 (+2.83%)
DLTR : 111.35 (-4.37%)
MYGN : 4.28 (+7.81%)
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

SALT LAKE CITY, May 07, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate...

MYGN : 4.28 (+7.81%)
MYGN Q1 Deep Dive: Hereditary Cancer Strength, Launch Investments Pressure Margins

MYGN Q1 Deep Dive: Hereditary Cancer Strength, Launch Investments Pressure Margins

MYGN : 4.28 (+7.81%)
Myriad: Q1 Earnings Snapshot

Myriad: Q1 Earnings Snapshot

MYGN : 4.28 (+7.81%)
Myriad Genetics (NASDAQ:MYGN) Misses Q1 CY2026 Sales Expectations, Stock Drops 16.2%

Myriad Genetics (NASDAQ:MYGN) Misses Q1 CY2026 Sales Expectations, Stock Drops 16.2%

MYGN : 4.28 (+7.81%)

Barchart Exclusives

Invest Like Warren Buffett and Buy Wide-Moat Stocks Via This ETF Ahead of a Major Market Shift
With index concentration at an all-time high, the stage is perfectly set for this ETF to make a solid comeback. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.